Khondrion, a Nijmegen, the Netherlands-based clinical-stage biopharmaceutical company developing therapies for primary mitochondrial disease (PMD), received an Innovation Credit of up to €5M from the Netherlands Enterprise Agency.
This government funding, matched by an investment from private backers, will fund Wave 1 of the company’s pivotal Phase 3 clinical trial of sonlicromanol. Sonlicromanol is a first-in-class small-molecule candidate therapy for m.3243A>G PMD, the most common genetic form of mitochondrial disease. The Phase 3 trial is expected to launch in H2-2025, marking a milestone in Khondrion’s mission to deliver the first approved treatment for these disorders.
The company intends to allocate the amount for the Wave 1 of its pivotal Phase 3 clinical trial of sonlicromanol.
Founded by Jan Smeitink, Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Its Lead pipeline asset, KH176, is a potential oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US.
The company work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of its potential medicines for patients with mitochondrial diseases
FinSMEs
06/05/2025